Biocompatibility of Thermally Hydrocarbonized Porous Silicon Nanoparticles and their Biodistribution in Rats
Source abstract
Abstract
Porous silicon (PSi) particles have been studied for the effects they elicit in Caco-2 and RAW 264.7 macrophage cells in terms of toxicity, oxidative stress, and inflammatory response. The most suitable particles were then functionalized with a novel (18)F label to assess their biodistribution after enteral and parenteral administration in a rat model. The results show that thermally hydrocarbonized porous silicon (THCPSi) nanoparticles did not induce any significant toxicity, oxidative stress, or inflammatory response in Caco-2 and RAW 264.7 macrophage cells. Fluorescently labeled nanoparticles were associated with the cells surface but were not extensively internalized. Biodistribution studies in rats using novel (18)F-labeled THCPSi nanoparticles demonstrated that the particles passed intact through the gastrointestinal tract after oral administration and were also not absorbed from a subcutaneous deposit. After intravenous administration, the particles were found mainly in the liver and spleen, indicating rapid removal from the circulation. Overall, these silicon-based nanosystems exhibit excellent in vivo stability, low cytotoxicity, and nonimmunogenic profiles, ideal for oral drug delivery purposes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Silicon Nanostructures and Photoluminescence · Nanoparticles: synthesis and applications · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Finland
Laboratory of Radiochemistry, Department of Chemistry, University of Helsinki, FI-00014 Finland
Laboratory of Industrial Physics, Department of Physics, University of Turku, FI-20014 Finland
Department of Physics, University of Kuopio, FI-70211 Kuopio, Finland
References (39)
Show source-provided references
1. Canham L. · Adv. Mater. · 1995 · 7 · 103310.1002/adma.19950071215 ↗
2. Anglin E. J. · Adv. Drug Delivery Rev. · 2008 · 60 · 126610.1016/j.addr.2008.03.017 ↗
3. Salonen J. · J. Pharm. Sci. · 2008 · 97 · 63210.1002/jps.20999 ↗
4. Santos H. A. · Acta Biomater. · 2010 · 6 · 272110.1016/j.actbio.2009.12.043 ↗
5. Santini J. T. · Nature · 1999 · 397 · 33510.1038/16898 ↗
6. Lin V. S. · Science · 1997 · 278 · 84010.1126/science.278.5339.840 ↗
7. Collins R. T. · Phys. Today · 1997 · 50 · 2410.1063/1.881650 ↗
8. Park J. H. · Nat. Mater. · 2009 · 8 · 33110.1038/nmat2398 ↗
9. Low S. P. · Biomaterials · 2009 · 30 · 287310.1016/j.biomaterials.2009.02.008 ↗
10. Cheng L. · Br J Ophthalmol. · 2008 · 92 · 70510.1136/bjo.2007.133587 ↗
11. Brayden D. J. · Drug Discovery Today · 2003 · 8 · 97610.1016/S1359-6446(03)02874-5 ↗
12. Salonen J. · J. Controlled Release · 2005 · 108 · 36210.1016/j.jconrel.2005.08.017 ↗
13. Foraker A. B. · Pharm. Res. · 2003 · 20 · 11010.1023/A:1022211127890 ↗
14. Kaukonen A. M. · Eur. J. Pharm. Biopharm. · 2007 · 66 · 34810.1016/j.ejpb.2006.11.021 ↗
15. Limnell T. · Int. J. Pharm. · 2007 · 343 · 14110.1016/j.ijpharm.2007.05.010 ↗
16. Wang F. · Mol. Pharm. · 2010 · 7 · 22710.1021/mp900221e ↗
17. Sudeep P. K. · Chem. Commun. (Cambridge) · 2008 · 612610.1039/b813025f ↗
18. Erogbogbo F. · ACS Nano · 2008 · 2 · 87310.1021/nn700319z ↗
19. Kilpelainen M. · J. Controlled Release · 2009 · 137 · 16610.1016/j.jconrel.2009.03.017 ↗
20. Heinrich J. L. · Science · 1992 · 255 · 6610.1126/science.255.5040.66 ↗
21. Nel A. · Science · 2006 · 311 · 62210.1126/science.1114397 ↗
22. Salonen J. · Appl. Surf. Sci. · 2004 · 225 · 38910.1016/j.apsusc.2003.10.028 ↗
23. Cai L. · Eur. J. Org. Chem. · 2008 · 2008 · 285310.1002/ejoc.200800114 ↗
24. Laaksonen T. · Chem. Res. Toxicol. · 2007 · 20 · 191310.1021/tx700326b ↗
25. AshaRani P. V. · ACS Nano · 2009 · 3 · 27910.1021/nn800596w ↗
26. Choi J. · J. Appl. Toxicol. · 2009 · 29 · 5210.1002/jat.1382 ↗
27. Jiang W. · Nat. Nanotechnol. · 2008 · 3 · 14510.1038/nnano.2008.30 ↗
28. Rejman J. · Biochem. J. · 2004 · 377 · 15910.1042/bj20031253 ↗
29. Chithrani B. D. · Nano Lett. · 2006 · 6 · 66210.1021/nl052396o ↗
30. Chapekar M. S. · J. Biomed. Mater. Res. · 1996 · 31 · 25110.1002/(SICI)1097-4636(199606)31:2<251::AID-JBM12>3.0.CO;2-O ↗
31. Tavares J. C. · Toxicology · 2009 · 262 · 13810.1016/j.tox.2009.05.020 ↗
32. Gratton S. E. · Proc. Natl. Acad. Sci. U.S.A. · 2008 · 105 · 1161310.1073/pnas.0801763105 ↗
33. Schou M. · Synapse · 2004 · 53 · 5710.1002/syn.20031 ↗
34. Charkes N. D. · J. Nucl. Med. · 1979 · 20 · 1150
35. Boukherroub R. · Chem. Mater. · 2001 · 13 · 200210.1021/cm000790b ↗
36. Bohn P. · Nucl. Med. Biol. · 2009 · 36 · 89510.1016/j.nucmedbio.2009.06.004 ↗
37. Mu L. · Angew. Chem., Int. Ed. · 2008 · 47 · 492210.1002/anie.200705854 ↗
38. Heikkila T. · Eur. J. Pharm. Biopharm. · 2010 · 74 · 48310.1016/j.ejpb.2009.12.006 ↗
39. Kocbach A. · Toxicol. Lett. · 2008 · 176 · 13110.1016/j.toxlet.2007.10.014 ↗